Final Appraisal Determination (FAD)
NICE issues final appraisal determination for Janssen’s psoriasis treatment
The National Institute for Health and Care Excellence (NICE) has issued its final appraisal determination (FAD) to Janssen recommending Tremfya (guselkumab) for treatment of adults with moderate to severe plaque psoriasis. Read more
Avelumab recommended for routine NHS use by NICE
A final appraisal determination (FAD) has been issued by the National Institute for Health and Care Excellence (NICE), recommending routine NHS use of avelumab for the treatment of adults in England, Wales and Northern Ireland with mMCC Read more
NICE recommends reimbursement of lenvatinib for thyroid cancer
The National Institute for Health and Care Excellence (NICE) has issued a final appraisal decision (FAD) recommending the reimbursement of lenvatinib (Lenvima) for the treatment of differentiated thyroid cancer. Read more
NICE recommends tivozanib as first-line treatment for kidney cancer
The National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending tivozanib as a first-line treatment option for advanced renal cell carcinoma (aRCC) in line with its licensed indication Read more
